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ABSTRACT 
Objective: Antiretroviral therapy (ART) is anticipated to result in an increase in long-term survival in human immunodeficiency virus (HIV) 
infected individuals, but may present with the development of associated complications including kidney damage. The present study aimed at 
assessing the kidney function estimated glomerular filtration (eGFR) rate and body mass index (BMI) of HIV seropositive subjects with or without 
HAART at Nnewi, Nigeria.  
Methods: A total of 90 subjects were recruited comprising of 30 HIV-seropositive on highly antiretroviral therapy (HAART), 30 HIV-seropositive 
drug naive, and 30 HIV-seronegative (control subjects). Anthropometric parameters of the subjects were assessed using a well-structured 
questionnaire. Five millilitres of blood sample was collected from the patients and used for the estimation of urea, creatinine, uric acid, serum total 
protein and cluster of differentiation (CD4) T-cell counts using diacetyl monoxime method, Jaffe-slot method, Caraway phosphotungstic acid 
method, refractometry and flow cytometric method respectively.  
Results: The result shows significantly higher mean serum urea, creatinine and uric acid levels in HIV seropositive drug-naive subjects and HIV 
seropositive subjects on HAART when compared with control (p<0.05). Similar observation were made with same parameters between HIV 
seropositive drug-naive subjects and HIV subjects on HAART (p<0.05). However, total protein and CD4 T-cells counts were significantly lower in 
HIV seropositive drug-naive subjects compared with HIV subjects on HAART and controls (p<0.05). Based on the chronic kidney disease 
epidemiology collaboration (CKD-EPI) equation, 6 (20.0%) of HIV seropositive subjects on antiretroviral therapy had a mild renal impairment, 
while 2 (6.6%) had a moderate renal impairment. Based on the modification of diet in renal disease (MDRD) equation, 7 (23.3%) of HIV subjects on 
therapy had mild renal impairment while 2 (6.6%) had a moderate renal impairment. Among the HIV drug naïve subjects, 8(26.7%) had mild renal 
impairment based on both equations. However, there were no significant differences in BMI and eGFR between HIV seropositive subjects on 
therapy and HIV seropositive drug-naive subjects.  
Conclusion: The present study shows evidence of significant alterations in serum urea, creatinine, and uric acid levels with mild and moderate state 
of renal impairment in HIV infected subjects with or without therapy. The significantly lower CD4 count and serum total protein in HIV naive 
subjects compared with HIV on HAART and control indicates reduced cellular immunity. Routine kidney function test using longitudinal study and 
more sensitive predictors for renal damage are recommended to ascertain the clearer picture of renal disease burden among HIV subjects in this 
environment. 
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Human immunodeficiency virus infection has become a public health 
challenge in the modern world today [1]. About 36.7 million people 
were living with HIV at the end of 2015 globally [2] and the incidence 
of HIV in Nigeria is 3.2% [3]. Infection with the HIV affects several 
body organs and systems, including the kidneys. The kidneys are the 
primary means for eliminating waste products of metabolism that are 
no longer needed by the body. These products include urea, creatinine, 
uric acid, bilirubin and metabolites of various hormones. These waste 
products must be eliminated from the body as rapidly as they are 
produced. Most toxins which are produced by the body or ingested 
and other foreign substances such as pesticides, drugs, and food 
additives are also eliminated through the kidneys [4]. 
The process of filtering these waste products from the blood and 
excreting them in the urine is one of the metabolic functions of the 
kidney and the rates at which these substances are excreted in the 
urine represent the sum of three renal processes which are 
glomerular filtration, reabsorption of substances from the renal 
tubules into the blood, and secretion of substances from the blood 
into the renal tubules [4]. 
Glomerular filtration rate (GFR) measures the rate at which 
substances are filtered from the blood into the urine. The 
development of formula-based calculation of eGFR has offered a 
very practical and easy approach for converting serum creatinine 
value into GFR result taking into consideration patient’s age, sex, 
ethnicity and weight depending on equation type. The commonly 
used equations include Cockcroft and Gault (1976), MDRD (1999) 
and CKD-EPI (2009) [5]. Hence, cystatin C, blood urea, creatinine, 
uric acid and eGFR can be used to assess kidney functions. The blood 
levels of these substances are usually raised above the reference 
ranges as a result of impaired kidney functions [6]. Diabetes, high 
blood pressure, age, race, obesity, high cholesterol, lack of physical 
exercise, smoking, and excessive salt intake are factors that increase 
the risk of kidney disease. Other contributing circumstances include 
infections or inflammatory diseases that affect the kidney; 
inappropriate use of medications like aspirin, ibuprofen, and other 
painkillers [7]. Human immunodeficiency virus/Acquired 
immunodeficiency syndrome (HIV/AIDS) infection has also been 
known to cause renal disease in infected patients. Renal disease is 
also becoming more prevalent in HIV-infected patients. The renal 
impairment can present as acute or chronic kidney disease; it can be 
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caused directly or indirectly by HIV and/or by drug-related effects 
that are directly nephrotoxic or lead to changes in renal function by 
inducing metabolic vasculopathy and renal damage [8]. Renal 
damage caused by HAART can result in a variety of toxic drug effects 
presenting as an acute renal failure, tubular necrosis, kidney stones, 
or chronic renal disease [8]. For example, long-term use of tenofovir 
disoproxil is associated with nephrotoxicity and bone loss. 
Presentation of nephrotoxicity can appear as Fanconi syndrome, 
acute kidney injury, or decline of GFR. Nephrotoxicity may be due to 
proximal tubules accumulation of tenofovir disoproxil leading to 
elevated serum concentrations [9]. Recent reports have linked 
HAART regimens that contain tenofovir to a mild, time-dependent 
elevation in the serum creatinine level and a decrease in the 
glomerular filtration rate [10]. Furthermore, a study has attributed the 
high prevalence of hyperuricemia seen in HIV-positive patients to the 
use of antiretroviral therapy such as a combination of didanosine and 
stavudine [11]. More so, an increase in the serum creatinine level 
frequently preceded by sterile leucocyturia, which normalized after its 
discontinuation, has been observed with indinavir treatment [8]. 
Ritonavir use has also been linked to reversible renal failure with an 
increase in the serum creatinine level [12]. However, the underlying 
mechanism behind nephrotoxicity in antiretroviral therapy is not fully 
understood. Since there is a correlation between the use of 
antiretroviral therapy in HIV/AIDS subjects and renal disease, the 
present study aims at assessing kidney function, estimated glomerular 
filtration rate and body mass index in HIV seropositive subjects with 
or without therapy at NAUTH, Nnewi, Nigeria.  
MATERIALS AND METHODS 
Study design 
This was a cross-sectional study designed to assess kidney function, 
body mass index and estimated glomerular filtration rate in HIV 
seropositive subjects with or without HAART attending HIV outpatient 
clinic at Nnamdi Azikiwe University Teaching Hospital, Nnewi, 
Anambra State Nigeria. The study was carried out between June and 
August 2017. The study participants comprised of a total of 90 
subjects aged 18-65 y, out of which 30 (Female =21, Male =9) were 
HIV seropositive subjects who had been receiving HAART for not less 
than least 6 mo, they were recruited at HIV clinic during their routine 
follow up at the clinic. 30 (Female = 18, Male =12) were HIV 
seropositive drug-naive subjects who were recruited at Heart to Heart 
Centre at their initial visit while 30 (Female = 17, Male =13) were HIV 
seronegative subjects regarded as a control group. They were 
apparently healthy individuals recruited among the hospital staff. 
Five (5) ml of blood was collected aseptically by venepuncture with 
vacutainer needles and syringe and dispensed into ethylenediamine-
tetraacetic acid-anticoagulated containers for CD4+count. Also, 
another 5 ml of blood was collected and dispensed into plain tubes, 
centrifuged at 5,000 rpm for 5 min and the serum separated and 
stored at-20˚C until assayed for urea, creatinine and uric acid. Other 
biodata were collected using a pre-tested interviewer-administered 
questionnaire. 
The heights of the subjects were measured with a metre rule and 
their weights measured with a weighing scale. Their body mass 
index was then calculated by the formula described by Gadzik, [13] 
where BMI = 𝒎𝒎𝒎𝒎𝒎𝒎𝒎𝒎(𝒌𝒌𝒌𝒌)
𝒉𝒉𝒉𝒉𝒉𝒉𝒌𝒌𝒉𝒉𝒉𝒉(𝒎𝒎)²
 
Inclusion and exclusion criteria 
Asymptomatic HIV subjects in stage 1, symptomatic HIV subjects in 
stage 2 and symptomatic HIV subjects in stage 2 on therapy, and HIV 
seronegative subjects (control group) within the age bracket of 18-
65 y were included in this study. HIV subjects in stages 3 and 4 were 
excluded from the study. Those on HAART for less than 6 mo, 
pregnant and lactating women, those with documented 
hypertension, diabetes and those with known dyslipidaemia before 
the commencement of the study were excluded. Individuals who are 
outside the age bracket of 18-65 y were excluded from this study. 
Antiretroviral drugs administration 
Participants on antiretroviral therapy were given either of the 
following regimens: a generic fixed-dose combination of zidovudine 
(ZDV) 300 mg twice daily orally+lamivudine (3TC) 150 mg twice 
daily orally+nevirapine (NVP) 200 mg twice daily orally. 
(Zidovudine and lamivudine are nucleoside reverse transcriptase 
inhibitors while nevirapine is a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) or (2) Stavudine (D4T) 30 mg twice 
daily orally+lamivudine (3TC) 150 mg twice daily+
Ethical consideration and informed consent 
nevirapine (NVP) 
200 mg twice orally. (Stavudine is also a nucleoside reverse 
transcriptase inhibitor). 
The ethical approval for this research was obtained from the 
Nnamdi Azikiwe University Teaching Hospital ethics committee 
with ref NAUTH/CS/66/Vol.10/25/2017/006 in accordance with 
the Helsinki declaration by the world medical association (WMA) 
on the ethical principles for medical research involving human 
subjects [14]. Informed consent was obtained from each of the 
participants. 
Methods 
Determination of antibodies to HIV-1 and/or HIV-2 
HIV testing was performed using the national algorithm described 
by the World Health Organization [15]. The procedure involved 
serial testing by determine, uni-gold and stat-pak test kits.  
CD4+T-Cell count 
The Cluster of Differentiation count was performed by the method 
described by Greve, [16]. Principle: The mouse monoclonal antibody 
MEM-241 recognizes the human CD4 antigen, a transmembrane 
glycoprotein (55kD) of the immunoglobulin supergene family, 
present on a subset of lymphocytes (“helper/inducer” T-cells) and 
also expressed at a lower level on monocytes, tissue macrophages 
and granulocytes. The antigen-antibody reaction is quantitated 
using a partec flow cytometer which works on the principle of 
immunofluorescence. 
Estimation of urea 
Serum urea and creatinine estimation were performed by diacetyl 
monoxime and Jaffe-Slot methods respectively as described by 
Kaplan and Teng, [17]. Principle: Urea reacts with diacetyl 
monoxime under strongly acidic conditions in the presence of ferric 
ions and thiosemicarbazide to give a pink-coloured complex. 
Absorbance is read at 520 nm wavelength. While creatinine reacts 
with the picric acid in an alkaline medium to produce an orange-red 
complex. The rate of formation of colour is proportional to the 
creatinine concentration in the sample. Absorbance of the coloured 
complex is read at 510 nm wavelength using a spectrophotometer. 
Estimation of uric acid 
Uric acid was estimated by Caraway phosphotungstic acid method 
as described by Ingebretsen et al. [18]. Principle: Phosphotungstic 
acid oxidizes uric acid to allantoin. The reduction product of 
phosphotungstate in an alkaline medium is blue and is estimated by 
measuring absorbance at 700 nm wavelength. 
Determination of total protein by refractometry 
Principle: Refractometry is a rapid analytical method that is used to 
determine serum proteins when a very small volume of serum is 
needed. Total proteins are the major masses of the dissolved solids 
in blood plasma and are commonly measured by a hand-held 
refractometer. 50 μL of serum was placed between a cover glass and 
the prism by capillary action. The refractometer was held so that 
light is refracted through the serum layer. The refracted rays caused 
part of the field of view to light, producing a point at which there is a 
sharp line between light and dark. The number of protein at this line 
on the internal scale will be read in g/dl 
Estimated glomerular filtration rate 
Estimated glomerular filtration rate was calculated using the 
modification of diet in renal disease (MDRD) equation as described 
by Levey et al. [18, 19] and chronic kidney disease epidemiology 
collaboration (CKD-EPI) equation as described by Levey et al. [20]. 
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The MDRD formula 
For creatinine inµmol/l: 
eGFR (ml/min/1.73m2) =32788× (serum creatinine)-1.154 × (Age)-
°.203 ×  [1.210 if Black] ×[0.742 if female]. 
For creatinine in mg/dl: 
eGFR (ml/min/1.73m2) = 186 × (serum creatinine)-1.154× (Age)-
°
Where SCr is serum creatinine (mg/dL), k is 0.7 for females and 0.9 for 
males, a is-0.329 for females and-0.411 for males, min indicates the 
minimum of SCr/k or 1, and max indicates the maximum of SCr/k or 1. 
As separate equations for different populations: For creatinine 
(IDMS calibrated) in mg/dL:  
Black female: If serum creatinine (SCr)<= 0.7  
eGFR= 166 × (SCr/0.7)P-
203 ×  [1.210 if Black] ×[0.742 female]. 
The CKD-EPI equation  
eGFR= 141 × min (SCr/k, 1)a ×  max (SCr/k, 1)P-1.209× 0.993PAge×
 [1.018 if female] × [1.159 if Black] 
 °
If serum creatinine (SCr) > 0.7 
.329×  0.993PAge 
eGFR= 166 × (SCr/0.7)P-1.[20]9×  0.993PAge 
Black male: If serum creatinine (SCr) <=  0.9 
eGFR =  163 ×  (SCr/0.9)P- °
If serum creatinine (SCr) > 0.9 
eGFR =  163 ×  (SCr/0.9)P-1.209×  0.993PAge 
Statistical analysis 
.411×  0.993PAge 
The statistical analysis was performed using the independent 
students’-test and one-way ANOVA. Pearson correlation was used to 
determine the relationship between CD4 count and renal function 
parameters. Data were presented as mean±standard deviation (SD) 
and the level of significance was set at p ˂0.05. 
RESULTS 
Levels of urea, creatinine, uric acid, BMI, esGFR and CD4 count in 
control subjects, HIV seropositive subjects on HAART and HIV 
seropositive drug-naive subjects (mean±SD) 
Urea was significantly higher in HIV drug-naive subjects (4.42±1.57) 
and HIV subjects on HAART (3.77±1.00) when compared with 
control subjects (3.55±0.89) (p<0.05) and significantly higher in HIV 
drug-naive subjects (4.42±1.57) compared with HIV subjects on ART 
(3.77±1.00) (p<0.05). The mean value of creatinine was significantly 
higher in HIV drug-naive subjects (89.4±29.14) and HIV subjects on 
HAART (79.31±16.80) when compared with the value in control 
subjects (75.83±24.87) (p<0.05). A similar observation was made 
between HIV drug-naïve subjects (89.4±29.14) and HIV subjects on 
HAART (79.31±16.80) (p<0.05).  
The mean value of uric acid was significantly higher in HIV drug-
naive subjects (395.99±121.65) and HIV subjects on HAART 
(324.03±120.16) when compared with the value in control subjects 
(280.89±80.57)(p<0.05). The same observation was made between 
HIV drug-naive subjects (395.99±121.65) and HIV subjects on ART 
(324.03±120.16) (p<0.05). 
The mean serum level of total protein was significantly lower in 
lower in both HIV subjects on HAART (6.02±1.87) and HIV drug-
naive subjects (4.46±1.52) when compared with controls 
(7.13±2.80) (p<0.05). Similarly, serum total protein was significantly 
lower in HIV drug naïve subjects (4.46±1.52) when compared with 
the counterpart on HAART (6.02±1.87)(p<0.05) 
However, the mean CD4 T-cell count was significantly lower in HIV 
drug-naive subjects (401.25±90.01) when compared with the value 
in HIV seropositive HIV subjects on ART (655.00±121.65) and 
control subjects (701.44±130.06) (p<0.05 respectively)(table 1) 
 
Table 1: Levels of urea, creatinine, uric acid, CD4 count, BMI and eGFR in control, HIV seropositive on HAART and HIV seropositive drug 

































4.46±1.52 23.13±2.85 108.15±23.24 108.94±30.98 401.25±90.01 
f-value 3.313 2.261 8.865 4.511 0.890 0.124 0.614 4.089 
p-value 0.042 0.011 0.001 0.003 0.415 0.884 0.544 0.045 
A vs B 0.442 0.202 0.061 0.004 0.937 0.627 0.275 0.117 
A vs C 0.013 0.018 0.006 0.000 0.243 0.911 0.561 0.000 
B vs C 0.030 0.041 0.032 0.000 0.218 0.769 0.740 0.002 
Data was expressed in mean±SD, level of significance was represented at p<0.05, n= number of sample used per group of subjects = 30.  
 
Comparison of renal function among study participants based 
on the CKD-EPI and MDRD equations 
Based on the CKD-EPI equation, 23 (76.7%) in the control group had 
a normal renal function (e GFR≥ 90 ml/min) while 7 (23.3%) had 
mild or moderate renal impairment. Among HIV subjects on ART, 22 
(73.3%) had a normal renal function (e GFR≥ 9 0 ml/min) while 8 
(26.7%) had mild or moderate renal impairment. Among HIV drug-
naive subjects, 22 (73.3%) had a normal renal function (e GFR≥ 90 
ml/min) while 8 (26.7%) had a mild renal impairment.  
Based on the MDRD equation, 24 (80.0%) in the control group 
had a normal renal function (e GFR≥ 9 0 ml/min) while 6 (20.0%) 
had mild or moderate renal impairment. Among the HIV subjects 
on ART, 21 (70.0%) had a normal renal function (e GFR≥ 9 0 
ml/min) while 9 (30.0%) had mild or moderate renal 
impairment. In the Among HIV drug-naive subjects, 22 (73.3%) 
had normal renal function (e GFR≥ 9 0 ml/min) while 8(26.7%) 
had mild renal impairment. 
29(96.6%) of control participants had normal body mall index 
with 1(3.3%) overweight while in HIV seropositive subjects on 
HAART, 12 (40.0%) were overweight while 1(3.3%) was 
underweight. In the HIV seropositive drug-naive subjects, 20 
(66.7%) had a normal mean body mass index while 10 (33.3%) 
were overweight (table 2). 
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Table 2: Comparison of body mass index, renal function among study participants (CKD-EPI and MDRD) 
Parameter Control (n=30) HIV on HAART (n=30) HIV drug naive (n=30) 
CKD-EPI equation renal function    
Normal (e GFR ≥ 90 ml/min) 23 (76.7%) 22 (73.3%) 22(73.3.0%) 
Mild (e GFR 60-89 ml/min) 5(16.7%) 6(20.0%) 8(26.7%) 
Moderate (e GFR 30-59 ml/min) 2(6.6%) 2(6.6%) None 
Severe (e GFR 15-29 ml/min) None None None 
Renal failure (e GFR<15 ml/min) None None None 
MDRD equation    
Normal (e GFR ≥ 90 ml/min) 24 (80.0%) 21 (70.0%) 22(73.3%) 
Mild (e GFR 60-89 ml/min) 3(10.0%) 7(23.3%) 8(26.7%) 
Moderate (e GFR 30-59 ml/min) 3(10.0%) 7(23.3%) None 
Severe (e GFR 15-29 ml/min) None None None 
Renal failure (e GFR<15 ml/min) None None None 
BMI    
Normal (18.5-24.9 kg/m2 29(96.7%) ) 17 (56.6%) 20 (66.7%) 
Underweight (<18.5 kg/m2 0 ) 1(3.3%) 0 
Overweight (25.0-29.9 kg/m2 1(3.3%) ) 12 (40.0%) 10 (33.3%) 
CKD-EPI=Chronic kidney disease epidemiology collaboration. MDRD= Modification of diet in renal disease. eGFR= estimated glomerular filtration 
rate. n= number of sample used. 
 
DISCUSSION 
In the present study, urea was significantly higher in HIV drug-naive 
subjects and HIV subjects on HAART when compared with control 
subjects and significantly higher in HIV drug-naive subjects when 
compared with HIV subjects on HAART. This is in agreement with 
previous reports [21, 22]. The increased urea level in HIV infected 
subjects (though within the reference range) is an indication of 
future prerenal uremia and impaired kidney functions. This can be 
attributed to high protein intake, muscle wasting, nutrition or 
dehydration which is prevalent in HIV infection. It may also be as 
result of catabolism or excess production of urea in the affected 
individuals. Similar observations were made in the values of serum 
creatinine and uric acid level when compared in the same groups of 
subjects. This is consistent with the report of Reddy and Prasad [23]. 
Elevated creatinine levels in HIV subjects have also been reported in 
other studies [24-26]. The kidneys excrete a variety of waste 
products produced by metabolism into the urine. These include the 
nitrogenous wastes urea, from protein catabolism, uric acid from 
nucleic acid metabolism, and creatinine from muscle creatine [4]. 
HIV/AIDS infection has also been known to cause renal disease in 
infected patients. Studies have shown that there is significant renal 
impairment among HIV-infected patients who are naive to HAART 
[21]. In a recent study, a prospective analysis of 754 HIV-infected 
patients reported an incidence of 5.9% [27]. In Ghana, it has been 
established that there is renal dysfunction among both patients on 
HAART and those yet to start HAART, and it was suggested that 
there is need for dose adjustments, especially before onset of 
therapy [28]. At all stages of HIV infection, renal disorders may be 
evident, ranging from fluid and electrolyte imbalances to end-stage 
renal disease (ESRD). Loss of kidney function may be attributable to 
treatment-related factors, intermittent viraemia, and traditional risk 
factors for kidney disease [29]. Renal damage caused by 
antiretroviral drugs can result in a variety of toxic drug effects 
presenting as acute renal failure, tubular necrosis, kidney stones, or 
chronic renal disease [8]. Renal dysfunction may, therefore, be a 
common finding in patients infected with HIV, and necessitates 
increased surveillance and adaptation of dosages of HIV drugs [8]. 
Knowledge on the renal function status of such individuals from 
time to time, will improve management strategies [30].  
Hyperuricemia is multifactorial in origin in HIV patients. Elevated 
uric acid level observed in the present study has been attributed to 
increased cell turnover [31, 32]. Reports have implicated increased 
uric acid levels to HIV infection itself and alteration in the HAART 
regimen such as didanosine or stavudine or both combinations [33]. 
The author attributed the association between dideoxynucleoside 
analogues (Stavudine and didanosine) and elevated urate to 
respiratory chain failure which causes ATP depletion thereby 
increasing urate production in the purine nucleotide cycle. This 
leads to mitochondria dysfunction and increased lactate which 
competes with urate for tubular excretion in the kidney. Other 
reports have also shown that hyperuricemia in HIV infection could 
result from low CD4 T-Cell, co-infection with either hepatitis B or C 
virus and other immunological and pathological conditions that 
characterize HIV disease progression [11].  
The study observed significantly lower serum total protein in both 
HIV drug-naive subjects and HIV subjects on HAART when 
compared with controls. This is consistent with previous reports 
[34, 35]. However, another study by Audu et al. [36] reported higher 
levels of total protein in HIV patients. Reports have shown that 
reduction in serum total protein in HIV infection may be due to 
increased losses and/or catabolism, malabsorption, fatigue, fever, 
depression and adverse drug effects [36].  
In the present study, 12 (40.0%) of HIV seropositive subjects on 
antiretroviral therapy were overweight, 1(3.3%) were underweight 
while 17 (56.6%) had a normal mean body mass index. This 
contrasts the observation in control subjects where 29(96.6%) had 
normal body mass index with 1(3.3%) overweight. This is similar to 
the findings of Carolline et al. [37] who reported the prevalence rate 
of 32.1% overweight and 8.8% underweight in HIV seropositive 
subjects on therapy. In the HIV seropositive drug naïve subjects, 20 
(66.7%) had normal mean body mass index while 10 (33.3%) were 
overweight. The prevalence of overweight among HIV drug naïve 
subjects in this study (33.3%) is comparable to the findings of 
Anyabolu [38] who reported 38.4% overweight in newly diagnosed 
HIV subjects. Studies on BMI in HIV subjects have shown an 
increasing prevalence of overweight and obesity more than 
underweight [39, 40]. Seroconversion, changes in metabolism and 
co-morbidities in the early phases of HIV infection have been shown 
to influence weight in these subjects [41, 42]. The nutritional 
changes experienced by individuals living with HIV/AIDS seem to be 
related both to the recent use of HAART and to the dietary patterns 
and habits of each population [43]. Although antiretroviral therapy 
has influenced the pattern of weight changes in HIV subjects, factors 
associated with underweight, or overweight/obesity in drug-naive 
individuals with HIV infection, are not completely known [39]. 
The present study observed no significant difference in eGFR 
between HIV seropositive subjects on therapy and HIV seropositive 
drug-naive subjects with mild and moderate incidence of renal 
impairment. Studies have shown that HAART reduces the 
progression of HIV to AIDS and prevents the development of HIV 
induced ESRD [44]. Some reports have also shown that HAART is 
associated with decreased prevalence of renal disease and 
amelioration of progression in the general population and in HIV 
infected patients with chronic renal disease [45-47]. Some degrees 
of adverse drug reactions have been reported after the use of 
HAART in HIV infected subjects including the use of second-line 
regimen [48] However, studies have reported cases of kidney 
disease after the introduction of tenofovir-containing HAART [9,49]. 
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Other drugs (Indinavir, efavirenz and keletra) have also been 
incriminated as the cause of kidney disease in HIV positive 
individuals. All these drugs are used in cases of proven toxicity with 
other drugs. On the other hand, it has been noted previously that 
HIV/AIDS develops more rapidly in infected patients in blacks, 
playing a very crucial role in the low prevalence as well as delaying 
the development of renal disease before death of the patients [50, 
51]. However, our study subjects did not use any of these 
combinations and there was no adverse reaction reported by the 
subjects at the time of the study. The reduction in renal damage in 
the present study may be attributed to absence of adverse drug 
reactions observed during the course of the study. It may be due to 
increased CD4 T-cell counts above 250/μl recorded in these 
subjects. A further longitudinal study using more sensitive 
predictors of renal damage in HIV infected individuals with or 
without therapy is strictly recommended in the study area. This 
would throw more light on identifying the pattern of renal disease 
and possible genetic as well as environmental factors associated 
with kidney disease in this environment.  
  In this study, there was an increase in the mean CD4+T-cell count in 
HIV seropositive subjects on HAART and control subjects when 
compared with that of HIV seropositive drug-naive subjects. This 
finding is still consistent with our previous reports [52, 53]. 
Obirikorang et al. [54] however, observed an increase in mean CD4 
count in HIV seropositive naïve subjects when compared with HIV 
seropositive subjects on HAART. Low CD4 count<200 cells/µl has 
been implicated with kidney disease [55, 56]. Contrastingly, several 
researchers reported increased CD4+T-cell count as a high-risk 
factor for developing renal toxicity [49, 57–59].   
CONCLUSION 
The present study showed evidence of mild and moderate changes 
in renal function in HIV infected subjects with or without therapy. 
This suggests the role of HIV infection, antiretroviral therapy and 
the presence of other traditional risk factors prior to the infection. 
Assessment of kidney function in HIV seropositive subjects before 
and during antiretroviral therapy is recommended. This is to aid in 
the selection of drug combinations and dose adjustments to achieve 
the desired therapeutic effects while minimizing the risk of drug 
adverse effects. More so, it is recommended that further research be 
carried out to elucidate the mechanisms underlying variations in 
kidney function and disease progression among HIV seropositive 
subjects on and off antiretroviral therapy. 
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